试验效果不及礼来，诺和诺德美股盘前股价大跌逾14%

Core Insights - Novo Nordisk's stock price dropped over 14% in pre-market trading on February 23 due to disappointing clinical trial results for CagriSema [1] Group 1: Clinical Trial Results - The REDEFINE 4 trial for CagriSema showed a weight reduction effect of 23% [1] - However, the study did not meet its predefined primary endpoint [1] - The efficacy of CagriSema was reported to be inferior compared to Eli Lilly's Zepbound [1]